PDS Biotechnology Corp (PDSB)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$21.7M
Cash & Equivalents
$4.4M
Quarterly Burn Rate
15 mo
Est. Cash Runway
$43M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma PHASE3 Active Not Recruiting 252

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for PDSB.

SEC EDGAR Filings

All SEC filings for PDS Biotechnology Corp on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.